GSK has expanded its collaboration with Chai Discovery to apply AI-powered protein modelling and molecular design tools across pharmaceutical drug discovery following successful laboratory validation.

Horizon Space Acquisition I Corp. has agreed to combine with ArcheNova Biotech in a transaction valuing the clinical-stage biotechnology company at approximately $2 billion.

Pfizer has entered a research and licensing collaboration with Enodia Therapeutics worth potentially more than $500 million to develop small-molecule therapies targeting protein synthesis through Sec61 inhibition.

Eli Lilly and Gate Bioscience have expanded their drug-discovery collaboration by adding a new target and an option for a second under Gate's Molecular Gate platform.

Lilly and InnoCare have entered a multi-target research and licensing collaboration potentially worth $3.35 billion to discover and develop new medicines.

Arcturus Therapeutics has agreed to acquire Belgian AI drug-discovery company myNEO, expanding its computational capabilities for mRNA medicine design and target identification.

AVS Bio has acquired Biorbyt, expanding its global life-sciences platform with a catalogue of more than one million antibodies, proteins and other research reagents.

The agreement gives Novartis options to secure exclusive rights to develop and commercialise multiple subcutaneous products using Alteogen's ALT-B4 Hybrozyme technology.

Biocytogen has granted Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody from its RenNano platform for the development of neuroscience therapies.

TScan Therapeutics is cutting approximately 75% of its workforce and pausing further enrolment in its Phase 3 ALLOHA-2 study as it redirects resources towards in vivo cell therapy programmes for solid tumours.

Novacyt and Illumina have entered into a five-year master collaboration agreement to explore molecular-diagnostics product development and commercial opportunities.

ArsenalBio is cutting 99 jobs as it restructures the company around a strategic shift towards in vivo CAR-T development.

The agreement gives Roche exclusive global rights to develop, manufacture and commercialise Simcere Zaiming's investigational trispecific antibody SIM0660 outside Greater China.

Lilly’s planned acquisition of Merida Biosciences adds an antibody-engineering platform designed to selectively remove disease-causing antibodies while preserving normal immune function.

The transaction combines Valerio’s targeted delivery technologies with Etherna’s mRNA, lipid nanoparticle and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.